NeoGenomics, Inc. Net Income 2010–2025
NeoGenomics, Inc. reported $-108.03M of net income for fiscal 2025. That was 37.2% lower than fiscal 2024. Compared with fiscal 2020, the change was -2689.3%.
| Fiscal year | Net Income | Net margin | Change (YoY) |
|---|---|---|---|
| FY 2025 | $-108.03M | -14.9% | -37.2% |
| FY 2024 | $-78.73M | -11.9% | +10.5% |
| FY 2023 | $-87.97M | -14.9% | +39.0% |
| FY 2022 | $-144.25M | -28.3% | -1628.2% |
| FY 2021 | $-8.35M | -1.7% | -300.1% |
| FY 2020 | $4.17M | 0.9% | -47.9% |
| FY 2019 | $8.01M | 2.0% | +203.3% |
| FY 2018 | $2.64M | 1.0% | +766.7% |
| FY 2017 | $-396,000 | -0.2% | +93.6% |
| FY 2016 | $-6.14M | -2.6% | -142.3% |
| FY 2015 | $-2.54M | — | -323.9% |
| FY 2014 | $1.13M | — | -44.3% |
| FY 2013 | $2.03M | — | +3027.7% |
| FY 2012 | $65,000 | — | +105.5% |
| FY 2011 | $-1.18M | — | +64.4% |
| FY 2010 | $-3.30M | — | — |
Source: NeoGenomics, Inc. SEC filings — income statement (10-K). Computed deterministically; refreshed nightly (last updated August 2, 2026). Open NEO 10-K filings at SEC EDGAR · Methodology · Download CSV.
How to read this history
NeoGenomics, Inc. reported $-108.03M of net income for fiscal 2025. That was 37.2% lower than fiscal 2024. Compared with fiscal 2020, the change was -2689.3%. Values remain missing when the cached filing does not disclose a comparable line item; they are never estimated. Stock splits, reorganizations and fiscal-calendar changes can reduce comparability.
Prepared and reviewed by the stockportfolio.pro research desk. Corrections: support@stockportfolio.pro.
See the full picture for NeoGenomics, Inc.
Complete income statement, balance sheet and cash flow with trend on every row, 48 quarters, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open the interactive view — freeNeoGenomics, Inc. — frequently asked questions
What is NeoGenomics, Inc.'s net income?
NeoGenomics, Inc. (NEO) reported net income of $-108.03M for fiscal year 2025, per its SEC filings.
Where does this data come from?
Figures are computed from NeoGenomics, Inc.'s official SEC filings (income statement (10-K)), refreshed nightly. Not investment advice.